Zhejiang Huahai Pharmaceutical Co., Ltd. Class A

Zhejiang Huahai Pharmaceutical Co., Ltd. Class A

SSSE:600521
16.61
CNY
+0.09
(+0.54%)
0.61EPS
25.78P/E
24.47BMarket Cap
Apr 27Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.79
1.93
2.58
3.03
3.63
3.88
3.88
4.46
4.63
5.73
5.7
6.57
5.8
6.44
Basic EPS, GAAP
0.28
0.2
0.33
0.37
0.46
0.08
0.41
0.64
0.34
0.81
0.57
0.77
0.18
0.63
Free Cash Flow per Basic Share
0.02
-0.08
-0.24
-0.22
-0.11
-0.8
0.69
0.19
-1.04
-0.74
0.43
0.22
-0.5
- -
Dividend per Share
0.11
0.14
0.1
0.14
0.18
0.23
0.15
0.27
0.27
0.22
0.38
0.33
0.37
0.22
Book Value per Share
2.23
2.39
2.64
3.18
3.55
2.96
3.86
4.48
4.4
5.09
5.45
6.07
6.31
6.72
Tangible Book Value per Share
2.02
2.11
2.28
2.78
2.98
2.28
3.16
3.61
3.36
3.84
4.12
4.58
4.78
5.13
Basic Weighted Avg Shares
1,284
1,340
1,358
1,349
1,379
1,314
1,389
1,453
1,434
1,442
1,457
1,453
1,480
1,492
Sales/Revenue/Turnover
2,296
2,585
3,500
4,093
5,002
5,095
5,388
6,485
6,644
8,266
8,309
9,547
8,587
9,603
Operating Margin (%)
18.07
13.34
15.23
12.84
17.92
15.24
20.39
24.19
9.6
20.79
18.47
19.08
9.71
15.48
Depreciation Expense
132
152
198
251
290
345
411
471
563
672
780
917
1,011
- -
Net Income, GAAP
359
266
442
501
639
108
570
930
488
1,168
830
1,119
266
946
Effective Tax Rate (%)
11.85
17.96
16.62
19.43
19.98
14.21
20.25
18.16
38.92
22.06
25.73
24.33
48.79
22.49
Profit Margin (%)
15.64
10.27
12.64
12.24
12.78
2.11
10.57
14.34
7.34
14.13
10
11.72
3.1
9.85
Working Capital
1,239
1,160
1,149
1,998
1,237
446
1,910
3,622
2,577
3,109
2,176
2,507
-370
1,567
LT Debt
43
- -
- -
535
222
900
1,179
2,963
3,564
4,694
4,067
4,411
1,917
3,316
Total Equity
3,019
3,266
3,720
4,578
5,055
4,207
5,779
6,724
6,776
7,746
8,251
9,020
9,456
10,338
Return on Invested Capital (%)
11.56
6.76
9.75
8.02
10.07
5.54
7.82
10.51
4.5
8.79
5.55
7.01
1.38
4.89
Return on Capital (%)
12.76
8.04
11.14
11.27
11.23
2.74
8.45
9.8
5.13
9.85
6.8
8.17
2.5
6.4
Return on Common Equity (%)
14.52
8.53
12.99
12.56
13.8
2.4
11.77
15.34
7.46
16.56
10.63
13.18
2.91
9.47

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
6,407
5,827
5,217
LT Borrowings
2,238
2,373
3,310
LT Finance Leases
25
5
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,497
1,497
1,497
Market Capitalization
24,046
21,560
24,465

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
9,219
8,965
9,441
Cash, Cash Equivalents & STI
1,975
1,962
2,264
Accounts Receivable, Net
2,720
2,972
2,986
Inventories
3,646
3,596
3,633
Total Current Liabilities
9,105
8,558
7,874
Payables & Accruals
- -
- -
- -
ST Debt
6,407
5,827
5,217
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.62%
7.15%
4.83%
Free Cash Flow
-91.26%
-240.41%
-330.47%
Net Income, GAAP
47.23%
4.32%
-76.19%
Sales/Revenue/Turnover
9.93%
6.45%
-10.06%
Total Cash Common Dividend
20.48%
11.17%
14.9%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,499
2,630
2,119
2,300
9,547
2025
2,369
2,148
- -
2,178
8,587
2026
2,335
2,577
2,512
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.19
0.33
0.2
0.06
0.77
2025
0.21
0.08
- -
-0.08
0.18
2026
0.27
0.25
0.19
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.03
0.22
0.04
0.33
2025
0.03
0.02
- -
0.04
0.37
2026
0.02
0.12
0.02
- -
- -

Company Description

CEO
Bao Hua Chen
Full Time Employees
8,797
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 88, Xunda Road Linhai ZH China 317024
IPO Date
Mar 4, 2003
Business
Zhejiang Huahai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients (APIs), pharmaceutical preparations, intermediates, packaging components, and related services; Zhejiang Huahai Pharmaceutical Co., Ltd. operates globally from its headquarters in Linhai, Zhejiang Province, China, where it was founded in 1989, with over 40 subsidiaries and branches in countries including the United States, Japan, Germany, Russia, Spain, and India. The company's core products encompass APIs and preparations focused on cardiovascular therapies such as irbesartan, losartan potassium, olmesartan medoxomil, valsartan, telmisartan, and amlodipine; central nervous system drugs including paroxetine hydrochloride, olanzapine, duloxetine hydrochloride, bupropion hydrochloride, and levetiracetam; anti-viral and anti-infective agents like oseltamivir phosphate, efavirenz, voriconazole, and doxycycline hydrochloride; as well as oncology products such as epirubicin hydrochloride injection, alongside biopharmaceuticals in autoimmunity and oncology fields, generic drugs across digestive, respiratory, endocrine, and anti-cancer categories, and contract manufacturing organization (CMO) services. Zhejiang Huahai Pharmaceutical Co., Ltd. serves over 500 pharmaceutical partners worldwide, supplying products to approximately 200 countries and regions, with significant export markets in North America, Europe, and Asia representing over 50% of sales. In recent developments, a subsidiary received US FDA good manufacturing practice pre-approval inspection in September 2025; the company reported nine-month sales of CNY 6.41 billion as of September 30, 2025; Zhejiang Huahai Pharmaceutical Technology Co., Ltd. announced a CNY 200 million funding round in March 2025 with participation from the parent company; and ongoing investments include R&D expansions and international production capacity, such as a 7 billion tablets facility in Charlotte, US.